Fluid Dynamics in the HeartMate 3: Influence of the Artificial Pulse Feature and Residual Cardiac Pulsation.

Artificial pulse Cardiac cycle Computational fluid dynamics HeartMate 3 Hemocompatibility Ventricular assist devices

Journal

Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 24 05 2018
revised: 22 07 2018
accepted: 15 08 2018
pubmed: 22 8 2018
medline: 6 8 2019
entrez: 22 8 2018
Statut: ppublish

Résumé

Ventricular assist devices (VADs), among which the HeartMate 3 (HM3) is the latest clinically approved representative, are often the therapy of choice for patients with end-stage heart failure. Despite advances in the prevention of pump thrombosis, rates of stroke and bleeding remain high. These complications are attributed to the flow field within the VAD, among other factors. One of the HM3's characteristic features is an artificial pulse that changes the rotor speed periodically by 4000 rpm, which is meant to reduce zones of recirculation and stasis. In this study, we investigated the effect of this speed modulation on the flow fields and stresses using high-resolution computational fluid dynamics. To this end, we compared Eulerian and Lagrangian features of the flow fields during constant pump operation, during operation with the artificial pulse feature, and with the effect of the residual native cardiac cycle. We observed good washout in all investigated situations, which may explain the low incidence rates of pump thrombosis. The artificial pulse had no additional benefit on scalar washout performance, but it induced rapid variations in the flow velocity and its gradients. This may be relevant for the removal of deposits in the pump. Overall, we found that viscous stresses in the HM3 were lower than in other current VADs. However, the artificial pulse substantially increased turbulence, and thereby also total stresses, which may contribute to clinically observed issues related to hemocompatibility.

Identifiants

pubmed: 30129977
doi: 10.1111/aor.13346
doi:

Types de publication

Journal Article

Langues

eng

Pagination

363-376

Subventions

Organisme : Universität Zürich
ID : Forschungskredit grant FK-17-040
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 200021_147193 CINDY
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : NCCR Kidney.CH
Organisme : National Science Foundation
Organisme : University of Zurich
Organisme : Stavros Niarchos Foundation
Organisme : University of Zurich
ID : FK-17-040
Organisme : National Science Foundation
ID : 200021_147193 CINDY
Organisme : National Science Foundation
ID : NCCR Kidney.CH

Informations de copyright

© 2018 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Auteurs

Lena Wiegmann (L)

The Interface Group, Institute of Physiology, University of Zurich, Zurich, Switzerland.

Bente Thamsen (B)

Pediatric Cardiovascular Surgery, Pediatric Heart Center, Department of Surgery, University Children's Hospital Zurich, Zurich, Switzerland.
Children's Research Center, University Children's Hospital Zurich, Switzerland.
Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.

Diane de Zélicourt (D)

The Interface Group, Institute of Physiology, University of Zurich, Zurich, Switzerland.
Children's Research Center, University Children's Hospital Zurich, Switzerland.

Marcus Granegger (M)

Pediatric Cardiovascular Surgery, Pediatric Heart Center, Department of Surgery, University Children's Hospital Zurich, Zurich, Switzerland.

Stefan Boës (S)

Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.

Marianne Schmid Daners (M)

Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.

Mirko Meboldt (M)

Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland.

Vartan Kurtcuoglu (V)

The Interface Group, Institute of Physiology, University of Zurich, Zurich, Switzerland.
National Center of Competence in Research, Kidney CH, Zurich, Switzerland.
Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH